---

Review on Alzheimer’s disease

Full Text PDF

---

Review Article

Author Details : Rimjhim Arora*, Kamal Singh Rathore, Surendra Singh Saurabh

Volume : 11, Issue : 2, Year : 2024

Article Page : 141-146

https://doi.org/10.18231/j.ijpca.2024.019

Suggest article by email

Get Permission

Abstract

The treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD) is crucial for individuals with the condition. Cholinesterase inhibitors (CIs) and memantine, used for cognitive symptoms, may have some effect on BPSD, but additional drugs may be needed as BPSD worsens. Selective serotonin reuptake inhibitors (SSRIs) like fluoxetine, sertraline, and others are effective antidepressants for comorbid depression in AD. Limited evidence supports their use for treating depression, agitation, and psychosis in AD, but recent trials showed no benefit and increased risks. Non-pharmacological interventions such as psycho social approaches and alternative therapies are important. A comprehensive approach combining medication and non-pharmacological interventions, along with close monitoring, is essential for managing BPSD and improving quality of life for individuals with AD and their caregivers.

Keywords: Alzheimer's disease (AD), Behavioral and psychological symptoms of dementia (BPSD), Cholinesterase inhibitors (CIs)

How to cite : Arora R, Rathore K S, Saurabh S S, Review on Alzheimer’s disease. Int J Pharm Chem Anal 2024;11(2):141-146

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.